Related references
Note: Only part of the references are listed.PD-L1 expression combined with microsatellite instability/CD8+tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer
Toshiaki Morihiro et al.
SCIENTIFIC REPORTS (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
CD39+ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function
Filip Ahlmanner et al.
Oncotarget (2018)
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Arabella Young et al.
CANCER RESEARCH (2018)
ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori
Hirotsugu Nagase et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Gastric cancer tissue-derived mesenchymal stem cells impact peripheral blood mononuclear cells via disruption of Treg/Th17 balance to promote gastric cancer progression
Mei Wang et al.
EXPERIMENTAL CELL RESEARCH (2017)
Targeting adenosine in cancer immunotherapy: a review of recent progress
Theresa L. Whiteside
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Tumoral FOXP3 expression is associated with favorable clinicopathological variables and good prognosis in gastric adenocarcinoma: the tumor suppressor function of tumoral FOXP3 is related with the P21 expression in gastric adenocarcinoma
Kyu Yeoun Won et al.
HUMAN PATHOLOGY (2017)
Adenosine metabolism of human mesenchymal stromal cells isolated from patients with head and neck squamous cell carcinoma
Patrick J. Schuler et al.
IMMUNOBIOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Cervical cancer cells suppress effector functions of cytotoxic T cells through the adenosinergic pathway
M. L. Mora-Garcia et al.
CELLULAR IMMUNOLOGY (2017)
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Arabella Young et al.
CANCER CELL (2016)
Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement
Rony Dahan et al.
CANCER CELL (2016)
Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
Hilmar Weinmann
CHEMMEDCHEM (2016)
A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer
Stephen M. Hatfield et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
A Metabolic immune Checkpoint: Adenosine in Tumor Microenvironment
Akio Ohta
FRONTIERS IN IMMUNOLOGY (2016)
Immunotherapy for Gastroesophageal Cancer
Emily F. Goode et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Adenosine Stimulate Proliferation and Migration in Triple Negative Breast Cancer Cells
Miriam Fernandez-Gallardo et al.
PLOS ONE (2016)
Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets
Laurent Muller et al.
SCIENTIFIC REPORTS (2016)
Effects of aqueous extract from Silybum marianum on adenosine deaminase activity in cancerous and noncancerous human gastric and colon tissues
Bahadir Ozturk et al.
PHARMACOGNOSY MAGAZINE (2015)
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Stephen M. Hatfield et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Robert D. Leone et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Anti-CD73 therapy impairs tumor angiogenesis
Bertrand Allard et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection
Stephen M. Hatfield et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID
Aisha V. Sauer et al.
BLOOD (2012)
Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells
Thomas Duhen et al.
BLOOD (2012)
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
John Stagg et al.
CANCER RESEARCH (2011)
Adenosine in the Inflamed Gut: A Janus Faced Compound
A. B. Estrela et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition
Charles P. Sevigny et al.
JOURNAL OF IMMUNOLOGY (2007)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Share Paper
